药石科技(300725) - 2025 Q1 - 季度财报

Revenue and Profit - The company's revenue for Q1 2025 was ¥455,018,107.75, representing a 20.55% increase compared to ¥377,460,431.51 in the same period last year[5] - Net profit attributable to shareholders decreased by 27.67% to ¥35,790,750.96 from ¥49,485,359.20 year-on-year[5] - Basic earnings per share fell by 28.00% to ¥0.18, compared to ¥0.25 in the same period last year[5] - Total operating revenue for the current period reached ¥455,018,107.75, an increase of 20.5% compared to ¥377,460,431.51 in the previous period[18] - Net profit for the current period was ¥35,790,750.96, a decrease of 27.7% from ¥49,485,359.20 in the previous period[19] - Earnings per share (EPS) for the current period was ¥0.18, down from ¥0.25 in the previous period[19] Cash Flow and Liquidity - The net cash flow from operating activities surged by 356.06% to ¥252,341,548.08, up from ¥55,330,257.73 in the previous year[5] - Cash inflow from operating activities totaled ¥680,318,835.89, up from ¥464,763,229.08, indicating a year-over-year increase of 46.3%[21] - Cash outflow from operating activities was ¥427,977,287.81, compared to ¥409,432,971.35, reflecting a slight increase of 4.2%[21] - The net increase in cash and cash equivalents was ¥355,283,193.12, contrasting with a decrease of ¥68,173,430.97 in the previous period[22] - The ending balance of cash and cash equivalents stood at ¥645,483,817.56, up from ¥440,098,278.17, reflecting an increase of 46.6%[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,914,980,393.45, a slight decrease of 0.41% from ¥4,935,272,666.40 at the end of the previous year[5] - Total liabilities decreased to ¥1,890,748,249.96 from ¥1,947,719,670.04[17] - Total equity attributable to shareholders increased to ¥3,024,232,143.49 from ¥2,987,552,996.36[17] Research and Development - The company's R&D expenses decreased by 37.53% to ¥21,559,149.46 from ¥34,513,051.40 year-on-year, reflecting ongoing adjustments in business layout[8] - Research and development expenses were ¥21,559,149.46, down from ¥34,513,051.40 in the previous period, indicating a focus on cost management[18] Operating Costs and Income - The company experienced a 46.54% rise in operating costs, totaling ¥316,982,758.01, attributed to revenue growth and market competition[8] - Total operating costs amounted to ¥412,531,258.48, up 26.8% from ¥325,204,409.51 in the prior period[18] - The company recorded a 310.18% increase in investment income to ¥4,356,576.46, compared to a loss of ¥2,072,743.28 in the previous year[8] Shareholder Information - The total number of common shareholders at the end of the reporting period is 33,741[10] - The top shareholder, Yang Minmin, holds 20.73% of the shares, amounting to 41,403,319 shares[10] - The company has a total of 0 preferred shareholders with voting rights restored[10] - The company has no changes in the number of preferred shareholders or restricted shares during the reporting period[12] Miscellaneous - The company reported a significant increase in contract liabilities by 74.31% to ¥97,821,118.13, indicating pre-received sales not yet recognized as revenue[8] - The company reported a significant increase in other revenue categories, with a 615.29% rise in miscellaneous income[13] - The company's inventory decreased to ¥780,902,805.72 from ¥840,165,143.36[15] - The total assets at the end of the reporting period are ¥2,713,972,014.09, slightly down from ¥2,716,938,169.24[15] - The company's first quarter report was not audited, as stated in the financial disclosures[23]